IL276386B2 - Heterocyclic nitrogenated amide compounds, preparations containing them and their uses - Google Patents

Heterocyclic nitrogenated amide compounds, preparations containing them and their uses

Info

Publication number
IL276386B2
IL276386B2 IL276386A IL27638620A IL276386B2 IL 276386 B2 IL276386 B2 IL 276386B2 IL 276386 A IL276386 A IL 276386A IL 27638620 A IL27638620 A IL 27638620A IL 276386 B2 IL276386 B2 IL 276386B2
Authority
IL
Israel
Prior art keywords
formula
pharmaceutically acceptable
acceptable salt
compound
compound represented
Prior art date
Application number
IL276386A
Other languages
English (en)
Hebrew (he)
Other versions
IL276386A (en
Original Assignee
Japan Tobacco Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Japan Tobacco Inc filed Critical Japan Tobacco Inc
Publication of IL276386A publication Critical patent/IL276386A/en
Publication of IL276386B2 publication Critical patent/IL276386B2/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/472Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/99Enzyme inactivation by chemical treatment

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
IL276386A 2018-02-01 2020-07-29 Heterocyclic nitrogenated amide compounds, preparations containing them and their uses IL276386B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2018016328 2018-02-01
PCT/JP2019/003052 WO2019151274A1 (ja) 2018-02-01 2019-01-30 含窒素複素環アミド化合物及びその医薬用途

Publications (2)

Publication Number Publication Date
IL276386A IL276386A (en) 2020-09-30
IL276386B2 true IL276386B2 (en) 2023-06-01

Family

ID=67479787

Family Applications (1)

Application Number Title Priority Date Filing Date
IL276386A IL276386B2 (en) 2018-02-01 2020-07-29 Heterocyclic nitrogenated amide compounds, preparations containing them and their uses

Country Status (21)

Country Link
US (4) US10800784B2 (https=)
EP (1) EP3747888A4 (https=)
JP (3) JP7241556B2 (https=)
KR (1) KR102725118B1 (https=)
CN (1) CN111655692B (https=)
AR (1) AR114237A1 (https=)
AU (1) AU2019214048B2 (https=)
BR (1) BR112020014177A2 (https=)
CA (1) CA3090219A1 (https=)
CL (1) CL2020002003A1 (https=)
CO (1) CO2020009420A2 (https=)
IL (1) IL276386B2 (https=)
MX (1) MX2020008126A (https=)
MY (1) MY205011A (https=)
PE (1) PE20211273A1 (https=)
PH (1) PH12020500613A1 (https=)
SA (1) SA520412473B1 (https=)
SG (1) SG11202006916SA (https=)
TW (1) TWI803570B (https=)
WO (1) WO2019151274A1 (https=)
ZA (1) ZA202004548B (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220362215A1 (en) 2018-09-11 2022-11-17 Japan Tobacco Inc. Therapeutic or prophylactic agent for chronic kidney disease containing pyrazole-amide compound
CN110407744A (zh) * 2019-08-13 2019-11-05 上海毕得医药科技有限公司 一种1-(4-氨基吡啶-2-基)乙酮的合成方法
CN119841865A (zh) 2020-02-07 2025-04-18 加舒布鲁姆生物公司 杂环glp-1激动剂
PL4116301T3 (pl) * 2020-03-04 2026-02-16 Japan Tobacco Inc. Skondensowany związek tricykliczny i jego zastosowanie medyczne
EP4211139A4 (en) * 2020-09-10 2024-12-18 Gasherbrum Bio, Inc. HETEROCYCLIC GLP-1 AGONISTS
JP7599039B2 (ja) * 2021-03-23 2024-12-12 上海海雁医薬科技有限公司 複素環置換ケトン類誘導体、その組成物および医薬における使用
CN117897382A (zh) * 2021-09-01 2024-04-16 日本烟草产业株式会社 含氮三环化合物及其药物用途
AU2024222719A1 (en) 2023-02-16 2025-08-21 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7943617B2 (en) * 2006-11-27 2011-05-17 Bristol-Myers Squibb Company Heterobicyclic compounds useful as kinase inhibitors
WO2008132162A1 (en) 2007-04-26 2008-11-06 Boehringer Ingelheim International Gmbh 3- (sulphonylamino) -phenyl-2 -hydroxy-ethylamino derivatives useful as beta-agonists, processes for preparing them and their use as medicaments
MX2009013130A (es) * 2007-06-01 2010-01-15 Schering Corp Moduladores de gamma secretasa.
EP2090576A1 (en) * 2008-02-01 2009-08-19 Merz Pharma GmbH & Co.KGaA 6-halo-pyrazolo[1,5-a]pyridines, a process for their preparation and their use as metabotropic glutamate receptor (mGluR) modulators
AR074797A1 (es) * 2008-10-10 2011-02-16 Japan Tobacco Inc Compuesto de fluoreno , composiciones farmaceuticas , inhibidores de pdhk y pdhk2 , metodos de tratamiento , usos de los mismos y kit comercial
BR112013033098B8 (pt) 2011-06-27 2021-03-23 Alectos Therapeutics Inc inibidores de glicosidade seletivos e usos dos mesmos
AU2012339870B2 (en) * 2011-11-15 2017-06-29 Merck Sharp & Dohme Corp. Substituted cyclopropyl compounds useful as GPR119 agonists
PT2858986T (pt) * 2012-06-12 2019-11-29 Chong Kun Dang Pharmaceutical Corp Derivados de piperidina como agonistas de gpr119
CN103570725B (zh) 2012-08-01 2017-03-22 中国科学院上海药物研究所 哌嗪并三唑类化合物及其制备方法和用途
MY182884A (en) * 2013-03-15 2021-02-05 Japan Tobacco Inc Pyrazole-amide compound and medicinal uses therefor
JP2015028009A (ja) * 2013-07-01 2015-02-12 日本たばこ産業株式会社 ピラゾール−アルコール化合物およびその医薬用途
TW201536748A (zh) * 2013-07-01 2015-10-01 Japan Tobacco Inc 茀-醯胺化合物及其醫藥用途
GB201316823D0 (en) * 2013-09-23 2013-11-06 R & D Vernalis Ltd New Chemical Entities
SG11201604940VA (en) 2013-12-17 2016-07-28 Merck Patent Gmbh N1-(3,3,3-trifluoro-2-hydroxo-2-methylpropionyl)-piperidine derivatives as inhibitors of pyruvate dehydrogenase kinase
CA2994027C (en) 2015-07-31 2023-10-10 Merck Patent Gmbh Bicyclic heterocyclic derivatives
JP6923551B2 (ja) 2016-03-29 2021-08-18 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung ピルバートデヒドロゲナーゼキナーゼのインヒビターとしてのn1−(3,3,3−トリフルオロ−2−ヒドロキシ−2−メチルプロピオニル)−ピペリジン誘導体
US10428024B2 (en) * 2016-04-28 2019-10-01 Merck Patent Gmbh Piperidinyl derivatives
CN114716377A (zh) * 2016-07-29 2022-07-08 日本烟草产业株式会社 吡唑-酰胺化合物的制造方法
WO2018034918A1 (en) * 2016-08-15 2018-02-22 Merck Sharp & Dohme Corp. Compounds useful for altering the levels of bile acids for the treatment of diabetes and cardiometabolic disease
MX2019004859A (es) 2016-10-28 2019-06-20 H Lundbeck As Tratamientos de combinacion que comprenden la administracion de imidazopirazinonas.
RU2019109039A (ru) 2016-10-28 2020-11-30 Х. Лундбекк А/С Комбинированные средства для лечения, предусматривающего введение имидазопиразинонов, предназначенные для лечения психических и/или когнитивных расстройств
PL4116301T3 (pl) * 2020-03-04 2026-02-16 Japan Tobacco Inc. Skondensowany związek tricykliczny i jego zastosowanie medyczne
CN117897382A (zh) * 2021-09-01 2024-04-16 日本烟草产业株式会社 含氮三环化合物及其药物用途

Also Published As

Publication number Publication date
ZA202004548B (en) 2021-10-27
CN111655692B (zh) 2023-10-10
CA3090219A1 (en) 2019-08-08
US20200017505A1 (en) 2020-01-16
EP3747888A4 (en) 2021-12-15
SA520412473B1 (ar) 2023-02-12
EP3747888A1 (en) 2020-12-09
PH12020500613A1 (en) 2021-05-31
CL2020002003A1 (es) 2020-10-23
MY205011A (en) 2024-09-27
AR114237A1 (es) 2020-08-05
BR112020014177A2 (pt) 2020-12-08
US10800784B2 (en) 2020-10-13
TW201934553A (zh) 2019-09-01
AU2019214048B2 (en) 2023-03-16
KR20200115566A (ko) 2020-10-07
JP2019131544A (ja) 2019-08-08
IL276386A (en) 2020-09-30
PE20211273A1 (es) 2021-07-19
WO2019151274A1 (ja) 2019-08-08
US20210284644A1 (en) 2021-09-16
CN111655692A (zh) 2020-09-11
JP2023071925A (ja) 2023-05-23
US20240300952A1 (en) 2024-09-12
SG11202006916SA (en) 2020-08-28
MX2020008126A (es) 2020-09-18
US20260070910A1 (en) 2026-03-12
TWI803570B (zh) 2023-06-01
JP7241556B2 (ja) 2023-03-17
AU2019214048A1 (en) 2020-06-25
CO2020009420A2 (es) 2020-08-10
RU2020128593A (ru) 2022-03-03
KR102725118B1 (ko) 2024-11-04
JP2024116307A (ja) 2024-08-27

Similar Documents

Publication Publication Date Title
IL276386B2 (en) Heterocyclic nitrogenated amide compounds, preparations containing them and their uses
JP6208603B2 (ja) ピラゾール−アミド化合物およびその医薬用途
JP2015028010A (ja) フルオレン−アミド化合物およびその医薬用途
JP2015028009A (ja) ピラゾール−アルコール化合物およびその医薬用途
RS67408B1 (sr) Spojeno triciklično jedinjenje i njegova medicinska upotreba
US20140296316A1 (en) Hydrate and crystal of fluorene compounds
Ma et al. Emerging therapy strategies for energy metabolism in acute myocardial infarction
RU2833338C1 (ru) Конденсированное трициклическое соединение и его применение в медицине
KR20050036293A (ko) 나프토퀴논계 화합물을 함유한 세포질형 이소시트릭산탈수소화효소 활성 저해제 및 비만과 고지혈증 예방 또는치료용 약학적 조성물
WO2006087718A1 (en) Extension of lifespan with drugs
NO863386L (no) Analogifremgangsmaate for fremstilling av komplekser av visse cardiotoniske fosfodiesterase-inhibitorer og vannopploeselige vitaminer.
NZ712292A (en) Pyrazole-amide compound and medicinal uses therefor
NZ712292B2 (en) Pyrazole-amide compound and medicinal uses therefor
HK1215808B (en) Pyrazole-amide compound and medicinal uses therefor